title: Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study.
abstract: BACKGROUND
  The high incidence of cardiovascular disease in uremic patients makes it a major cause of morbidity and mortality in those patients. Uremia is associated with carbonyl and oxidative stress, which result in the enhanced formation of glycation and oxidation products respectively. In the present study, the blood levels of advanced glycation end products (AGEs) and advanced oxidation protein products (AOPPs) were investigated in uremic patients prior to and after initiation of peritoneal dialysis (PD).
  
  
  METHODS
  22 patients [11 nondiabetic (G1) and 11 diabetic (G2) subjects] were enrolled in a single-center prospective study. Prior to starting PD (TO) and 6 and 12 months later, changes in AGE and AOPP levels were analyzed in the total study population and in each group (Friedman test, intragroup). At each time point, a comparison was made between the levels of the above-mentioned products in G1 and G2 (Mann-Whitney test, intergroup). Correlations between AGE or AOPP levels and residual renal function, peritoneal creatinine clearance, glucose peritoneal equilibration test, or daily dextrose exposure were analyzed using the Pearson test.
  
  
  RESULTS
  At TO, no significant difference was found between the two groups for AGE or AOPP levels. Initiation of PD was followed by an increase in AGE levels in all patients (p < 0.01 at 6 and 12 months). AGE Levels were higher in G2 than in G1 at 12 months after the start of PD (p < 0.05). In contrast to G2 results, initiation of PD in G1 led to reduced AOPP Levels (at 6 and 12 months, p = 0.01 and p < 0.05 respectively). However, no correlation between AGE or AOPP levels and residual renal function, peritoneal creatinine clearance, glucose peritoneal equilibration test, or daily dextrose exposure could be established.
  
  
  CONCLUSIONS
  This study demonstrates that PD is associated with an increase in levels of blood glycation end products, particularly in diabetic patients, but also with a decrease in oxidative products such as AOPPs, especially in nondiabetic subjects.
authors.affiliation: Laboratory of Vascular and Cellular Biology, National Institute of Blood Transfusion, France. dreboulanger@hotmail.com
authors.forename: Eric
authors.initials: E
authors.lastname: Boulanger
authors.forename: Olivier
authors.initials: O
authors.lastname: Moranne
authors.forename: Marie-Paule
authors.initials: MP
authors.lastname: Wautier
authors.forename: Véronique
authors.initials: V
authors.lastname: Witko-Sarsat
authors.forename: Béatrice
authors.initials: B
authors.lastname: Descamps-Latscha
authors.forename: Abdelmejid
authors.initials: A
authors.lastname: Kandoussi
authors.forename: Nicolas
authors.initials: N
authors.lastname: Grossin
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Wautier
mesh_terms: D015415:Biomarkers / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D010530:Peritoneal Dialysis; D010865:Pilot Projects; D011446:Prospective Studies; D011506:Proteins / Q000378:metabolism*; D014511:Uremia / Q000097:blood* / Q000628:therapy
chemical_list: D015415:Biomarkers; D017127:Glycation End Products, Advanced; D011506:Proteins